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Expression of the ZIP/SLC39A transporters
in β-cells: a systematic review and
integration of multiple datasets
Rebecca Lawson, Wolfgang Maret and Christer Hogstrand*
Abstract
Background: Pancreatic β-cells require a constant supply of zinc to maintain normal insulin secretory function.
Following co-exocytosis with insulin, zinc is replenished via the Zrt- and Irt-like (ZIP; SLC39A) family of transporters.
However the ZIP paralogues of particular importance for zinc uptake, and associations with β-cell function and
Type 2 Diabetes remain largely unexplored. We retrieved and statistically analysed publically available microarray
and RNA-seq datasets to perform a systematic review on the expression of β-cell SLC39A paralogues. We
complemented results with experimental data on expression profiling of human islets and mouse β-cell derived
MIN6 cells, and compared transcriptomic and proteomic sequence conservation between human, mouse and rat.
Results: The 14 ZIP paralogues have 73–98% amino sequence conservation between human and rodents. We
identified 18 datasets for β-cell SLC39A analysis, which compared relative expression to non-β-cells, and expression
in response to PDX-1 activity, cytokines, glucose and type 2 diabetic status. Published expression data demonstrate
enrichment of transcripts for ZIP7 and ZIP9 transporters within rodent β-cells and of ZIP6, ZIP7 and ZIP14 within
human β-cells, with ZIP1 most differentially expressed in response to cytokines and PDX-1 within rodent, and ZIP6
in response to diabetic status in human and glucose in rat. Our qPCR expression profiling data indicate that SLC39A6,
−9, −13, and − 14 are the highest expressed paralogues in human β-cells and Slc39a6 and −7 in MIN6 cells.
Conclusions: Our systematic review, expression profiling and sequence alignment reveal similarities and potentially
important differences in ZIP complements between human and rodent β-cells. We identify ZIP6, ZIP7, ZIP9, ZIP13
and ZIP14 in human and rodent and ZIP1 in rodent as potentially biologically important for β-cell zinc trafficking. We
propose ZIP6 and ZIP7 are key functional orthologues in human and rodent β-cells and highlight these zinc importers
as important targets for exploring associations between zinc status and normal physiology of β-cells and their decline
in Type 2 Diabetes.
Keywords: Type 2 diabetes, Zinc, ZIP, SLC39A, Systematic review, Expression data, Microarray, RNA-seq
Background
Pancreatic β-cells require a constant supply of zinc for
normal function in maintaining glycaemic control [1, 2].
Zinc acts at multiple stages within the insulin secretory
pathway [3, 4]. Zinc ions (Zn2+) are loaded into insulin
granules via the predominantly β-cell specific zinc
transporter 8 (ZnT8) [5], where two ions co-crystallise
with insulin hexamers [6], important for proper insulin pro-
cessing, protection of insulin from proteolytic degradation
[7] and for maintaining granule osmotic stability [8].
Zinc is subsequently co-released with mature insulin
upon exocytosis where it is proposed to fulfil additional
roles in glycaemic control [9–11].
Significant amounts of Zn2+ are lost from β-cells
during insulin secretion and coordinated replenishment
is required. The Zrt- and Irt-like (ZIP; SLC39A) family
of zinc importer proteins, of which 14 paralogues are
present within both humans and rodents [12, 13], tightly
control cellular Zn2+ influx into the cytosol and are
thought responsible for restoring β-cell zinc content
[14]. ZIP paralogues exhibit differing Zn2+ affinities
(K0.5) and transporting efficiencies, and show cell- and
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condition-dependent expression [12, 15], thus it is ex-
pected that the β-cell ZIP profile closely reflects the
unique cellular demand for Zn2+ and ability to adapt to
stresses such as hyperglycaemia and inflammatory c-
ytokines. Since both hyperzincemic and hypozincemic
Zn2+statuses are observed in diabetic patients [16–18] and
animal models of diabetes [19, 20], one can hypothesize
that altered ZIP expression profiles are associated with
disease state. However exploration of the β-cell SLC39A
transcriptome, and therefore the liable transporters, has
been limited to a few studies [4, 14, 21–23], where an im-
portance of ZIP4 [23], ZIP6 [21, 22], ZIP7 [14, 21, 22],
ZIP8 [22], and ZIP14 [14, 24] has been suggested.
Type 2 Diabetes is rapidly evolving into a major public
health crisis. The disease pathogenesis generally results
from an increasingly inadequate insulin response due to
enhanced insulin resistance and a compensatory demand
on insulin production that eventually leads to β-cell
failure. Multiple studies have associated diabetes with
hypozincemia, likely caused by hyperzincuria, and a
negative correlation between the glycated haemoglobin
percentage and plasma zinc [16–18]. Accordingly, there
is a positive effect of adequate plasma zinc levels on
glycemic control [18], suggesting a compromised zinc
status in diabetes [25].
Since zinc plays an integral role within β-cells, un-
derstanding its regulation may prove central for
targeting loss of secretory function during Type 2
Diabetes. Much of our understanding of β-cell physi-
ology has derived from studies on rodents due to very
limited accessibility of human islets [26]. However,
differences in physiology between humans and ro-
dents remain often unacknowledged when interpreting
rodent studies. We hypothesised that the ZIP trans-
porters most important to β-cells should be robustly
expressed and show enrichment relative to other cell
types [27], with changes in expression influenced by
cellular stresses associated with compromised insulin
secretion. We thereby aimed to identify and evaluate
the complement of ZIP transporters most important
within human and rodent (mouse and rat) β-cells for
regulating zinc influx and accumulation.
Here we show through systematic review of micro-
array and RNA-seq studies [28, 29] that transcripts for
multiple ZIP paralogues are enriched in β-cells and/or
show transcriptional regulation in response to cytokines,
hyperglycaemia, Type 2 Diabetes status, and pancreatic
and duodenal homeobox 1 (PDX-1) activity, the major
transcription factor for β-cells. We used quantitative
PCR (qPCR) to verify the relative expression of these
paralogues within human islets and/or murine MIN6 β-
cells. Furthermore, we computationally aligned human,
mouse and rat SLC39A mRNA and protein sequences to
demonstrate high cross-species conservation of the
paralogues identified as key for β-cell zinc homeostasis
within our systematic review. We highlight ZIP6, ZIP7,
ZIP9, ZIP13 and ZIP14 in human and rodent, and ZIP1
in rodent as biologically important candidates for medi-
ating β-cell Zn2+ influx and zinc-signalling processes,
such as cell proliferation. In addition to normal physi-
ology, we suggest ZIP6, ZIP7 and ZIP14 downregulation
is associated with diabetic status; however the
relationship to zinc content in the β-cells/pancreas
remains unknown. Critically, our review highlights po-
tentially important differences between human islets and
rodent cells in their complements of zinc importers,
again demonstrating the limitations of rodent models for
human diabetes.
Methods
Systematic review
Identification of eligible expression datasets
This systematic review was conducted in accordance
with the guidelines provided in the PRISMA statement.
Microarray and RNA-seq expression profiling studies
were identified through searching the NCBI PubMed
database and the Gene Expression Omnibus (GEO)
database [30] to April 2016, using combinations of the
following key terms: “β-cell, islet” and “diabetes, gene
expression, microarray, RNA-seq”, and compiled studies
screened for duplicates. Eligibility was independently
assessed through first screening by title and abstract,
and then by the full text, based on the following
inclusion criteria: original research article published in
English, RNA-seq or microarray platform, expression
profiling of mature β-cells, islets and/or β-cell line, and
human or rodent genome. The eligibility was finally
confirmed through verifying the presence of accessible
expression data for ZIP transporter transcripts (SLC39A/
Slc39a). Included datasets explored: (a) expression
within β-cells compared to non-β-cells, (b) expression in
response to extracellular cytokines, (c) expression in re-
sponse to PDX-1 activity, (d) expression in response to
extracellular glucose, and (e) expression within human
diabetic islets. From each identified dataset, the acces-
sion number (if appropriate), platform, species, sample
types and sizes, and gene expression data were extracted.
This pipeline is depicted in Fig. 1.
Data pre-processing
The heterogeneity of different platforms, gene nomen-
clature and control samples can cause difficulties when
comparing datasets from different sources. Normalisa-
tion is therefore critical to reduce the chance of skewing
the results and enhances credibility of individual expres-
sion changes. To minimise inconsistency, a standardised
normalisation method was performed within datasets
[31] using Qlucore Omics Explorer (version 3.2; Qlucore
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AB, Lund, Sweden). Raw data was log (base = 2; log2)
transformed and normalised through applying a
standard score (Z-score) transformation, which calcu-
lates normalised expression intensities (y_i) of each
probe as follows:
yi ¼ xi−m
δ
Where x_i represents raw intensity values (x_i,
i = 0…N-1) for each gene, m represents average gene
intensity for the experiment, and δ represents the
standard deviation of all measured intensities.
Statistical analysis
Statistical analysis was undertaken using the Qlucore
Omics Explorer (version 3.2; Qlucore AB, Lund,
Sweden) bioinformatics software. Fold differences (FD)
in expression between relevant conditions were derived,
and significance calculated on the global transcriptomic
data set through unpaired t-tests, adjusted using the
Benjamini-Hochberg False Discovery Rate (FDR) pro-
cedure [32]. Genes were considered differentially
expressed in comparisons at an FDR of 15%. Arbi-
trary FD cut offs of ≥1.5-fold on significantly
regulated genes were chosen to indicate biologically
relevant differential expression. Full results from
analysis are provided in Additional file 1.
Datasets with inaccessible raw data
Where the full raw datasets were not available for down-
load, normalised data were extracted from supplementary
data tables and log2 transformed FD (Log2FD) values and
significance extracted/calculated using Excel as appropri-
ate. Data analysed in this way are annotated.
Experimental analysis
Human islet cDNA
Human islet cDNA originating from healthy cadaver
donors was obtained via the Human Islet Isolation Unit
at King’s College Hospital.
Cell line and RNA extraction
The adherent insulinoma β-cell line MIN6 (Mus musculus)
was maintained within Dulbecco’s Modified Eagle’s
Medium supplemented with 15% fetal bovine serum,
4 mM L-glutamine, 50 μM β-mercaptoethanol, 100 μg/ml
streptomycin and 100 units/ml penicillin (both Sigma-
Aldrich), at 37 °C in a humidified atmosphere of 95% air
Fig. 1 The pipeline followed for identification of suitable microarray and RNA-seq datasets
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and 5% CO2. Total RNA was extracted using TRIzol
Reagent (ThermoFisher), reverse transcribed to cDNA
using the high capacity RNA-to-cDNA kit (ThermoFisher),
and diluted ≥1:10 prior to experimentation.
Quantitative PCR
Quantitative PCR (qPCR) assays were designed using the
online Universal Probe Library (UPL) assay design tool
(Roche). Assay designs are provided within Additional files 2
and 3: Tables S1 and S2. Primer Blast [33] was used to pre-
dict the binding of our primers to mouse and human
RNA. The mouse primers bind all respective ZIP trans-
porter isoforms. The human primers bind all isoforms for
ZIP2, ZIP4, ZIP5, ZIP6, ZIP8, ZIP10, ZIP11, ZIP12 and
ZIP13. Primers for ZIP1, ZIP3, ZIP7, ZIP9 and ZIP14
covered either all the isoforms expressed within human is-
lets, or those predominantly expressed (Additional files 2
and 3: Tables S1 and S2, Additional file 4). PCR plates
were loaded using the Biomek FX liquid handling robot
(Beckman Coulter) and reactions [20-40 μg cDNA,
0.1 μM UPL probe, 0.2 μM forward primer, 0.2 μM re-
verse primer and 1X TaqMan Fast Advanced Mastermix
(Applied Biosystems)] amplified using the Prism7900HT
sequence detection system, Applied Biosystems, and ana-
lysed with SDS (sequence detection systems) 2.4 software.
All gene expression values were normalised to the house-
keeping gene ubiquitin C (UBC), and relative expression
calculated using the ΔΔCT method. The efficiencies for
primers targeting genes with appreciable expression
(mouse: ZIP1, ZIP2, ZIP3, ZIP4, ZIP6, ZIP7, ZIP8, ZIP9,
ZIP10, ZIP11, ZIP13, ZIP14, UBC, GADPH; human: ZIP1,
ZIP3, ZIP4, ZIP5, ZIP6, ZIP7, ZIP8, ZIP9, ZIP10, ZIP13,
ZIP14, UBC, GADPH) ranged from 88 to 111% for mouse
and 75–106% for human. Data show an average of two
biological repeats for human islets and three biological
repeats for MIN6 cells.
Exploration of zinc transporter heterogeneity
Human and mouse ZIP orthologues were aligned to
assess transcriptomic and proteomic similarities using
MUSCLE (3.8) [34, 35] and percent similarity values
recorded.
Results
Overview of included datasets
A systematic review allows integrated analysis of multiple
high throughput gene expression datasets. Following the
pre-defined criteria, 18 appropriate β-cell/islet expression
profiling studies were identified. These studies are sum-
marised in Table 1. Seven studies compared expression
within β-cells to non-β-cells, four investigated expression
in response to extracellular cytokines, three studied
expression in response to PDX-1 activity, one explored
expression in response to extracellular glucose, and three
measured expression within human diabetic islets.
Specificity of ZIP transporter expression within β-cells
Multiple microarray and RNA-seq studies have sought
to assess β-cell gene expression relative to other pancre-
atic cells and additional tissues. Since ZIP paralogues
exhibit cell-specific profiles reflecting function [12, 15],
β-cell enrichment may indicate important cell-specific
roles. Analysis of human islet cell transcriptomics data-
sets uncovered SLC39A13 and SLC39A14 as enriched
within β-cells compared to α-cells [2- to 3-fold], and
SLC39A1, SLC39A10 and SLC39A11 as ≥1.5-fold de-
pleted [36, 37]. However, when β-cell expression was
compared to sorted pancreatic exocrine cell populations
(human duct and acinar cells), enrichment of SLC39A7
and SLC39A9 was observed (1.7- and 1.6-fold respect-
ively) alongside relative depletion of SLC39A5 (11-fold),
SLC39A8 (4.3-fold), SLC39A10 (1.8-fold) and SLC39A11
(1.5-fold) (data calculated from supplementary tables).
Similarly RNA-seq data from Nica et al. uncovered de-
pletion of SLC39A5 and SLC39A10 within sorted human
β-cells over both total islets (2- and 6.8-fold, respect-
ively) and non-β-cells [islet cell populations considered
depleted of β-cells (2.8- and 4-fold, respectively)],
accompanied by depletion of SLC39A2 (2-fold over total
islets and 4-fold over non-β-cells) and SLC39A3 (1.7-fold
over both total islets and non-β-cells), with enrichment
of SLC39A1 (2.4-fold over total islets and 2.1-fold over
non-β-cells), and of SLC39A14 (1.9-fold, only over non-
β-cell preparations) [38].
Analysis of microarray datasets of human β-cell-
enriched pancreatic samples and 15 other tissues [β-cell-
enriched pancreas, pancreatic duct cells, cerebrum,
colon, foetal brain, kidney, liver, lung, myocardial,
skeletal muscle, prostate, small intestine, spleen, stomach,
testis and thymus (dataset GSE30803)] revealed ≥1.5-fold
enrichment of SLC39A1, SLC39A6, SLC39A7 and
SLC39A14, however without statistical significance [39].
Further investigation of probe-specific expression revealed
that relative enrichment was biased by elevated expression
of specific paralogues within other tissues (ZIP6 within
the brain [40] and prostate [41], ZIP7 within the colon
[42] and ZIP14 within the liver [43]). Omitting these tis-
sues indicated ≥3-fold enrichment of SLC39A6 (q < 0.1)
and SLC39A14 (q < 0.15), and 1.6-fold SLC39A7 (q < 0.05)
enrichment within β-cells compared to the remaining
tissues analysed (Fig. 2a).
Analysis of a mouse RNA-seq dataset [44] suggested
Slc39a4, Slc39a5 and Slc39a8 are ≥4-fold depleted
within sorted β-cells over islets (Fig. 2b). Further investi-
gation of non-β-cell depleted paralogues compared to
total islets and six other cell types [brain, liver, lung fi-
broblasts, neural progenitor cells (NPC), skeletal muscle,
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total islet (Fig. 2c)] revealed Slc39a7 and Slc39a9 as the
most β-cell enriched Zip paralogues in mouse with 2.3-
and 3-fold elevated expression, respectively. Analysis of a
further rat dataset comparing expression of β-cells over α-
cells (dataset GSE13381) displayed ≥1.5-fold enrichment
of Slc39a3 and Slc39a6, and ≥2-fold enrichment of
Table 1 Overview of the datasets identified for analysis
Dataset ID Platform Species Sample Number of samples Reference
E-MTAB-463 and
E-MTAB-465
Agilent-014850 Whole
Human Genome
Microarray 4x44K G4112F
Homo sapiens β-cells and α-cells β-cells: 4
α-cells: 4
Dorrell et al., 2014
– RNA-seq Homo sapiens Sorted β-cells, α-cells and
exocrine cells (duct and
acinar)
β-cells: 3
α-cells: 3
Exocrine cells: 2
Bramswig et al., 2013
EGAS00001000442 RNA-seq Homo sapiens Sorted β-cells, α-cells and
non-β-cells
7 DNA libraries, pooled Nica et al., 2013
GSE30803 [HG-U133A] Affymetrix
Human Genome U133A
Array
Homo sapiens Islets (and 16 other
primary cell types)
Islets: 3 Martens et al., 2011
– RNA-seq Mus musculus β-cells and islets Unknown. Data for 5
additional cell types
downloaded from NCBI
Ku et al., 2012
GSE13381 [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus β-cells and α-cells β-cells: 2
Non-β-cells: 2
Kutlu et al., 2009
GSE10785 Rosetta/Merck Mouse
44 k 1.0 microarray
Mus musculus Islets (and 5 other
primary cell types)
Islets: 40 Keller et al., 2008
GSE35296 RNA-seq Homo sapiens Islets Control: 5
IL-1β and IFN-γ: 5
Eizirik et al., 2012
– [HG-U133A] Affymetrix
Human Genome U133A
Array
Homo sapiens Islets Control: 3
IL-1β and IFN-γ: 3
Ylipaasto et al., 2005
– [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus FACS purified β-cells For control and cytokine
stimulation at each time
point: 3
Ortis et al., 2010
– [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus INS-1E rat insulinoma
cell line
For control and cytokine
stimulation at each time
point: 3
Moore et al., 2011
GSE40642 [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus INS-1ab rat insulinoma
cell line
Control: 8
IL-1β: 20
PDX-1 overexpression: 8
PDX-1 overexpression
and IL-1β: 20
Hansen et al., 2012
GSE49786 [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus Islets Untreated: 5
Pdx-1 overexpression: 5
Hayes et al., 2013
E-MTAB-127 A-CBIL-10-UPenn Mouse
PancChip 6.1
Mus musculus Islets and MIN6 murine
insulinoma cell line
Islets Pdx-1+/−: 3
Islets Pdx-1+/+: 3
MIN6 treated: 4
MIN6 control: 4
Sachdeva et al., 2009
GSE12817 [Rat230_2] Affymetrix Rat
Genome 230 2.0 Array
Rattus norvegicus Islets 2 mM Glucose: 4
5 mM Glucose: 4
10 mM Glucose: 4
30 mM Glucose: 4
Bensellam et al., 2009
GSE25724 [HG-U133A] Affymetrix
Human Genome U133A
Array
Homo sapiens Islets Non-diabetic: 7
Diabetic: 6
Dominguez et al., 2011
GSE20966 [U133_X3P] Affymetrix
Human X3P Array
Homo sapiens β-cell-enriched pancreatic
tissue
Non-diabetic: 10
Diabetic: 10
Marselli et al., 2010
GSE38642 [HuGene-1_0-st]
Affymetrix Human Gene
1.0 ST Array [transcript
(gene) version]
Homo sapiens Islets Non-diabetic: 54
Diabetic: 9
Taneera et al., 2012
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Slc39a7 and Slc39a14, but without statistical significance.
However, there was no differential Slc39a expression be-
tween murine islets and five other tissues (adipose, gastro-
cnemius muscle, hypothalamus, liver, and soleus muscle)
from 10-week old lean and obese C57BL/6 and BTBR
mice (dataset GSE10785).
Cytokine stimulation and ZIP transporter expression
Pro-inflammatory cytokines profoundly affect cellular
metabolism and utilisation of nutrients such as metal
ions [45]. Chronic exposure of islets to the inflammatory
cytokines interleukin-1 beta (IL-1β), tumor necrosis
factor-alpha (TNF-α) and interferon-gamma (IFN-γ) is
associated with β-cell destruction and decreased
secretory parameters in both Type 1 and Type 2 Dia-
betes [46]. Cytokine-dependent expression may indicate
ZIP paralogues important for maintaining normal β-cell
parameters when adapting to extracellular cytokine
stress. RNA-seq dataset analysis of human islets exposed
to IL-1β and IFN-γ for two days (dataset GSE35296)
revealed 1.4- and 2.0-fold upregulation of SLC39A8 and
SLC39A14 transcripts, respectively, and 2-fold downreg-
ulation of SLC39A10 [47]. However an additional micro-
array study using human islets [48] did not show any
ZIP transporter transcripts differentially expressed
following 48 h incubation with IL-1β and IFN-γ.
Within independent studies, both fluorescence assisted
cell sorting (FACS) purified rat β-cells [49] and the rat
INS-1E β-cell line [50] were cultured with IL-1β and
IFN-γ before microarray analysis (data from both studies
calculated from supplementary data). Within rat β-cells
[49] differential regulation of Slc39a1 (2.5-fold) was
observed at 2 h, and of Slc39a1 and Slc39a10 at both
12 h (2.0- and −3.5-fold, respectively) and 24 h (1.5-fold
and −1.6-fold, respectively). Similarly, INS-1E cells [50]
displayed upregulation of Slc39a1 at both 6 and 24 h
(2.6- and 2.1-fold, respectively) and of Slc39a6 at 24 h
(1.7-fold), alongside downregulation of Slc39a13 at 6 h
(−1.5-fold). INS-1E cells were additionally analysed after
6 and 24 h incubation with IFN-γ and TNF-α to show
Slc39a1 upregulation (2.8- and 2.4-fold, respectively)
and Slc39a14 downregulation (2.8- and 2.4-fold,
respectively).
PDX-1 and ZIP transporter expression
PDX-1 is the key transcription factor mediating β-cell-
specific gene expression within developing and mature
β-cells [51]. Changes in ZIP expression as a consequence
of PDX-1 activity may indicate roles of respective
transporters in maintaining normal β-cell parameters.
Critically, constitutive overexpression of PDX-1 sensi-
tises β-cells to cytokine-induced apoptosis [52, 53].
Overexpression of PDX-1 within rat INS-1ab cells
(dataset GSE40642) resulted in downregulation of
Slc39a6 and Slc39a14 (Fig. 3). Stimulation of PDX-1
overexpressing cells with cytokine IL-1β further exacer-
bated these effects and also upregulated Slc39a1 ≥ 2.5-
fold [54] (Fig. 3). Whereas within rat islets (dataset
GSE49786), PDX-1 overexpression upregulated Slc39a8
(2.1-fold, P < 0.01) [55]; however Slc39a5 and Slc39a8
were up- and downregulated 1.5- and −2.6-fold, respect-
ively, in mouse MIN6 cells (dataset E-MTAB-127) [56].
Data analysis from E-MTAB-127 additionally showed
2.8-fold downregulation of Slc39a5 in PDX+/− mouse
islets compared to PDX+/+ control mouse islets.
Expression in response to glucose stimulation
Hyperglycaemia is universal within all prediabetic and
diabetic cases, and glucose-responsive expression may
indicate genes and pathways important for adapting to
an enhanced demand for insulin secretion. Examination
of microarray datasets of isolated rat islets cultured with
2 mM, 5 mM, 10 mM and 30 mM glucose (dataset
GSE12817) uncovered ≥1.5-fold upregulation of Slc39a2,
Slc39a4 and Slc39a6 and ≥1.5-fold downregulation of
Slc39a3 and Slc39a5 when glucose increases [57].
Fig. 2 Enrichment of SLC39A paralogues within human and murine β-cells. a Expression within human β-cell-enriched pancreatic samples
compared to 11 other tissues (pancreatic duct cells, cerebrum, kidney, lung, myocardial, skeletal muscle, small intestine, spleen, stomach, testis
and thymus). b Expression within sorted mouse β-cells compared to mouse islets. c Expression within sorted mouse β-cells compared to six other
cell types (brain, liver, lung fibroblasts, NPC, skeletal muscle, islets), after exclusion of β-cell depleted paralogues. Data for (a) analysed from dataset
GSE30803 and (b-c) analysed from supplementary tables within [44]. #P < 0.15, *P < 0.05, ***P < 0.001. NPC = neural progenitor cells
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Expression within islets from type 2 diabetic patients
Transcriptomic datasets of islets derived from normogly-
caemic and Type 2 diabetic patients were next analysed to
explore relevance to the human disease. Three paralogues
(SLC39A2, SLC39A5 and SLC39A8) showed ≥1.5-fold up-
regulation and four paralogues (SLC39A6, SLC39A7,
SLC39A8 and SLC39A14) ≥1.5-fold downregulation in
diabetic compared to non-diabetic individuals [results
combined from studies GSE25724 [58] and GSE20966
[59], Fig. 4]. However in a cohort of Nordic patients
(dataset GSE38642), no ZIP paralogues were found
differentially (≥1.5-fold) expressed between diabetic and
non-diabetic islets [60].
SLC39A Paralogues identified within our systematic
review are experimentally verified to show high
β-cell/islet expression and sequence conservation
Enhanced relative expression may suggest a biological
relevance of respective putative ZIP orthologues in
maintaining intracellular Zn2+ homeostasis in β-cells/is-
lets. To verify the biological relevance of the ZIP ortho-
logues we identified in our systematic review in terms of
β-cell function, we performed qPCR expression profiling
of human and mouse SLC39A mRNA transcripts. There
was notably a wider range of mRNA for ZIP transporters
expressed in human islets, compared with murine MIN6
cells. We observed highest expression of SLC39A6,
SLC39A9, SLC39A13 and SLC39A14 in human islets and
of Slc39a6 and Slc39a7 in mouse MIN6 cells (Fig. 5).
We next assessed cross-species homologies between
human and putative rodent ZIP orthologues. Enhanced
similarity increases the likelihood of inferring molecular
function [61], and increases confidence when applying
results encompassing data derived from multiple spe-
cies. We calculated the transcriptomic and proteomic
homologies between human and mouse ZIP ortholo-
gues, and between mouse and rat ZIP orthologues
through bioinformatics. We showed all respective
orthologues have high similarities, with lowest protein
homology between human and mouse observed for
ZIP4 (73%) and highest for ZIP1 (94%). All rat and
mouse orthologues showed protein similarities of ≥90%
aside from ZIP4 (89.8%) and ZIP14 (89.5%) (Table 2).
The high sequence similarities observed indicate that
all ZIP paralogues identified as important in our sys-
tematic review have the potential to substitute func-
tionally in human, mouse and rat β-cells.
Discussion
Associations between Zn2+ status and β-cell function have
been extensively described in independent studies [1, 2, 62].
ZnT8 expression is positively correlated with granule Zn2+
release and glucose tolerance in mice [63], and high glucose
stimulation increases free Zn2+ content within mouse islets
[22] and hamster HIT-T15 cells [64]. Intracellular Zn2+ ex-
hibits roles in protection against oxidative stress-induced
apoptosis [65] whereas chronic elevation contributes to β-
cell dysfunction [22]. The ZIP importer paralogues respon-
sible for maintaining β-cell Zn2+ homeostasis remain largely
unexplored and are important to investigate for under-
standing β-cell function in health and diabetic disease.
A systematic review allows integrated analysis of
relative consistencies in differential expression from high
throughput gene expression techniques, despite hetero-
geneities between studies involving experimental design
Fig. 4 SLC39A transcripts differentially expressed in human type 2
diabetic islets compared to non-diabetic islets. Probes targeting the
same transcript(s) are averaged for each assay. Black bars: data
analysed from dataset GSE25724; grey bars: data analysed from
dataset GSE20966. *P < 0.05
Fig. 3 Slc39a transcripts differentially expressed in rat INS-1ab cells
following PDX-1 overexpression and IL-1β stimulation. Black bars:
PDX-1 overexpression; dark grey bars: IL-1β stimulation; light grey
bars: PDX-1 overexpression and IL-1β stimulation. Data analysed
from dataset GSE40642. *P < 0.05, ***P < 0.001
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and platform used. It has the capacity to identify consist-
ent but modest variations, important for genes involved
in processes where small expression changes can have
amplified effects. Through this systematic review we re-
analysed raw microarray and RNA-seq data in parallel
with unannotated high-throughput datasets to compare
and contrast β-cell ZIP complemets in human, mouse
and rat β-cells/islets. We show enrichment of mRNA for
ZIP7 and ZIP9 within rodent and ZIP6, ZIP7 and ZIP14
within human, with mRNA for ZIP1, ZIP6 and ZIP14
differentially expressed in response to cytokines and
PDX-1 within rodent, and ZIP6 in response to diabetic
status in human and glucose in rat. To query the bio-
logical relevance of our data, we carried out experimen-
tal expression profiling of human islet and MIN6 β-cell
cDNA, and computationally aligned human, mouse and
rat mRNA and protein sequences. Highest expression
was observed for mRNA corresponding to ZIP6, ZIP9,
ZIP13 and ZIP14 in human islets and ZIP6 and ZIP7 in
mouse MIN6 cells, which is in agreement with previous
observations [21]. The mRNA profile for ZIPs generated
through our qPCR analyses also corresponds well to
expression data on specific isoforms in human islets
as produced by RNA-seq (Additional file 4). All ZIP
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Fig. 5 Expression profiles of SLC39A mRNA transcripts in human islets and murine MIN6 cells. a The human SLC39A transcriptome. N = 2 and error
bars show ± range. b The MIN6 β-cell Slc39a transcriptome. N = 3 and error bars show ±SEM
Table 2 Percentage similarity between human, mouse and rat ZIP/SLC39A protein and mRNA sequences
Gene Refseq transcript ID Entrez protein ID Percentage similarities
(human:mouse)
Percentage similarities
(mouse:rat)
Human Mouse Rat Human Mouse Rat Transcript Protein Transcript Protein
SLC39A1 NM_014437.4 NM_013901.2 NM_001134577.1 Q9NY26 Q9QZ03 B5DEF5 80.77 93.83 91.60 98.46
SLC39A2 NM_014579.3 NM_001039676.2 NM_001107260.1 Q9NP94 Q2HIZ9 D3ZIN1 78.51 77.99 91.87 94.82
SLC39A3 NM_144564.4 NM_134135.1 NM_001008356.1 Q9BRY0 Q99K24 Q5U1X7 80.99 84.04 91.23 97.16
SLC39A4 NM_017767.2 NM_028064.2 NM_001077669.1 Q6P5W5 Q78IQ7 A0JPN2 74.55 73.17 91.98 89.79
SLC39A5 NM_173596.2 NM_028051.3 NM_001108728.1 Q6ZMH5 Q9D856 D3ZSF7 83.42 84.30 92.24 94.00
SLC39A6 NM_012319.3 NM_139143.3 NM_001024745.1 Q13433 Q8C145 Q4V887 80.04 88.20 92.01 95.28
SLC39A7 NM_006979.2 NM_008202.2 NM_001164744.1 Q92504 Q31125 Q6MGB4 81.72 85.90 90.62 93.72
SLC39A8 NM_022154.5 NM_001135150.1 NM_001011952.1 Q9C0K1 Q91W10 Q5FVQ0 76.15 89.35 90.74 96.10
SLC39A9 NM_018375.4 NM_026244.2 NM_001034929.1 Q9NUM3 Q8BFU1 Q3KR82 78.04 93.49 93.35 92.33
SLC39A10 NM_001127257.1 NM_172653.2 NM_001108796.2 Q9ULF5 Q6P5F6 D4A517 84.50 87.36 92.25 96.16
SLC39A11 NM_001159770.1 NM_001166503.1 NM_001013042.1 Q8N1S5 Q8BWY7 Q6P6S2 77.62 90.32 91.32 95.22
SLC39A12 NM_001145195.1 NM_001012305.2 XM_006254285.3 Q504Y0 Q5FWH7 D4A8R5 78.31 78.17 91.15 90.41
SLC39A13 NM_001128225.2 NM_001290765.1 NM_001039196.1 Q96H72 Q8BZH0 Q2M1K6 81.54 90.58 93.42 93.84
SLC39A14 NM_001128431.2 NM_001135151.1 NM_001107275.1 Q15043 Q75N73 D3ZZM0 75.84 86.91 90.11 89.53
Comparisons were generated using Clustal multiple sequence alignment by MUSCLE (3.8) [34, 35]
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orthologues displayed high sequence conservation be-
tween species. Surprisingly ZIP4, which is essential for
intestinal zinc uptake in both mouse and human [27,
66], shows the lowest homology (73%) between these
two species and it also does not appear to play a major
role in β-cells. Based on their expression levels, relative
enrichment in β-cells/islets (compared with other cells/
tissues), and regulation in response to conditions rele-
vant to diabetes, we propose that ZIP6, ZIP7 and ZIP14
in human, and ZIP6 and ZIP7 in rodent may be of par-
ticular importance for β-cell Zn2+ uptake and/or homeo-
stasis. This conclusion is similar to that of Liu et al. [21],
who highlighted the roles of ZIP6 and ZIP7 in β-cell
zinc transport and viability. Our study also indentifies
ZIP1, ZIP9 and ZIP13 as being of potential additional
significance for β-cell function.
The abundance of ZIP transporters varies substantially
between tissues and cells, allowing those with differing
Zn2+ affinities, cellular localisations and regulatory
mechanisms to tightly maintain the homeostatic balance
[67]. We found significant differences in ZIP mRNA
abundance between β-cells and non-pancreatic tissues;
specifically, enrichment of ZIP7 and ZIP9 within mouse
β-cells, and ZIP6, ZIP7 and ZIP14 within human islets.
With the exception for ZIP7, which is found in the
endoplasmic reticulum (ER) and in some cells in the
Golgi apparatus, these zinc channels are operating at the
plasma membrane [13, 68]. ZIP6 and ZIP7 enrichment
is consistent with a report [21], suggesting that ZIP6 and
ZIP7 mediate influx of zinc into the β-cell cytosol in tan-
dem from the plasma membrane and the ER. In addition
to their roles in transporting zinc, ZIP6, ZIP7 and ZIP14
strongly stimulate cell proliferation, drastically increas-
ing the number of cells in G2/M phase, and their expres-
sion changes in cancers [27, 69–73]. Also of potential
importance is that ZIP14 mediates import of both zinc
and non-heme iron [74, 75] and that ZIP9 has been
identified as a plasma membrane androgen receptor
[76]. Interestingly, transcripts of ZIP9 and ZIP14, which
were both found expressed at comparable abundances to
ZIP6 and ZIP7 within human islets by ourselves and
others [21], were additionally enriched within β-cells.
ZIP9 and ZIP14 both show predicted localisation at the
plasma membrane (with localisation of ZIP9 at the Golgi
and trans-Golgi network additionally described) [77, 78],
and currently remain unexplored in this context. Our
expression profiling further identified ZIP13 as highly
expressed in both human islets and MIN6 cells. ZIP13 is
phylogenically grouped with ZIP7 [79] and studies have
suggested ZIP13 localises at the ER, Golgi [80, 81] and
intracellular vesicles [82]. However, to our knowledge
ZIP13 has not been studied in β-cells. ZIP9, ZIP13
and ZIP14 may represent novel targets for understand-
ing β-cell zinc uptake and homeostasis.
PDX-1 is the major transcriptional regulator in mature
β-cells and mediates expression of key β-cell genes, with
homozygous mutations linked to Type 2 Diabetes devel-
opment [83]. Furthermore, PDX-1 drives β-cell (re)gen-
eration from neurogenin-3 positive endocrine precursors
and pancreatic α-cells [84, 85], and β-cell-specific recov-
ery of activity within Ins2Akita mice (βPdx1; Ins2Akita
mice) promotes significantly improved glucose tolerance
compared to control littermates [86]. Of interest, PDX-1
binds enhancers (cis elements) of the ZnT8 gene
SLC30A8 [87], indicating a role of PDX-1 in β-cell zinc
homeostasis parallel to its role in insulin gene regulation
[88]. Our analysis suggests PDX-1 activity sensitizes the
β-cell zinc response to cytokines through ZIP6 and
ZIP14 downregulation and ZIP1 upregulation within rat
INS-1ab cells. We additionally established ZIP1 to be
consistently upregulated following stimulation with IL-
1β and IFN-γ, and IFN-γ and TNF-α within rat β-cells
[49] and INS-1E cells [50], highlighting ZIP1 as poten-
tially important in the adaptive response to cytokines.
Interestingly, ZIP1 and ZIP6 abundances have been
negatively correlated with the obesity-associated inflam-
matory state [89]. In contrast to the data in rodents, our
review further identified ZIP8 and ZIP14 upregulation in
response to the inflammatory cytokines IL-1β and IFN-γ
in human islets [47]. Inflammatory mediators such
as lipopolysaccharides (LPS) and TNF-α upregulate
SLC39A8 within human lung epithelia [90] and Slc39a14
is upregulated in response to LPS-initiated inflammation
within the mouse pancreas and liver [43] and shows an
acute-phase gene response to IL-6 [91].
Hyperglycaemia is well recognised as a universal driver
in the pathogenesis of Type 2 Diabetes [92]. Our analysis
showed high glucose stimulation of rat islets significantly
enhanced ZIP6 mRNA expression, consistent with
glucose-dependent increases of additional ZIP7 and
ZIP8 upregulation [22]. Similarly, analysis of islets from
human type 2 diabetic donors displayed ZIP6, ZIP7,
ZIP8 and ZIP14 mRNA downregulation compared to
normoglycaemic controls [58, 59]. Decreased transcript
expression supports a disease relevance of these paralo-
gues for mediating β-cell zinc accumulation, indicating
abnormally low zinc uptake may occur within diabetic
β-cells as a result of disrupted ZIP6, ZIP7, ZIP8 and/or
ZIP14 expression.
At a proteomic level no significant differences in
protein abundances were observed for any ZIP paralogue
within human islets incubated with high or low glucose
[93–95]. Though in one of these studies non-significant
trends for enrichment of ZIP6 (2.6-fold) and ZIP14 (1.6-
fold) in human islets were observed following culture in
high compared to low glucose [95]. However, these
proteomic studies likely bias towards proteins with
higher abundances [96], and accurately evaluating less
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abundant species away from central pathways and those
in complexes remains challenging, with membrane pro-
teins imposing further challenges [97]. Although it is ac-
knowledged that mRNA abundances often poorly
correlate with protein abundances and functional activity
[98], transcriptomic analysis remains important for pin-
pointing expression control and pathways of disruption
during disease states.
This systematic review provides an overview of ZIP
transcript expression in the context of β-cell specificity,
cytokine stimulation, PDX-1 activity, glucose status and
Type 2 Diabetes. It has allowed us to collectively analyse
ZIP expression within multiple high throughput datasets,
complemented by experimental work, providing evidence
for differential regulation as a consequence of β-cell
stresses associated with decreased insulin secretion. The
study’s limitations should nevertheless be acknowledged.
Firstly, although all raw datasets (if appropriate) were sub-
jected to the same normalisation process to minimise in-
consistencies, the platform and genomic heterogeneities
and differing probe hybridization efficiencies could skew
global interpretation, and the analysis used may not have
been equally suited to all datasets. Secondly, RNA-seq
offers unbiased analysis of sequences present however
microarray datasets are limited by hybridization
efficiencies and the probes present [99], such that in
multiple studies probes did not target all ZIP paralogues.
Multiple datasets analysed and our qPCR expression
data utilised islets incorporating non-β-cells. Relative
SLC39A abundances may be impacted by additional
cell populations, such as SLC39A14 enrichment in α-
cells [100]. Furthermore, although we have shown
high conservation of ZIP mRNA and protein sequences
between human and mouse, results may not be entirely
translatable across species. Finally, several microarray
studies identified within the systematic review search cri-
teria were excluded during the final screening due to the
absence of available experimental data for download and
analysis. Despite these limitations, our systematic review
distinguishes specific SLC39A paralogues as important
within each human and rodent β-cells. The results are
strongly supported by our experimental expression profil-
ing of human islet and MIN6 β-cell cDNA through con-
firming relative enrichment and a biological relevance.
Conclusions
We have used a systematic approach to identify key ZIP
complements in human, mouse and rat β-cells. We have
verified a biological importance of these paralogues
through proving high relative expression in human islets
and/or murine MIN6 β-cells, and have demonstrated
their potential to serve as functional orthologues in
human and rodent through verifying high sequence
similarities. Importantly, our results highlight similarities
and potentially biologically relevant differences in zinc
regulation between human and rodent ZIP orthologues
which may prove critical when evaluating rodent β-cell
models of disease. We propose ZIP6 and ZIP7 serve as
key functional rodent-human orthologues in β-cells. We
further identify ZIP9, ZIP13 and ZIP14 in human and
Fig. 6 Predicted subcellular localisation of the identified ZIP transporters within human and rodent β-cells. Based on the data analysed in the
present study ZIP6, ZIP7, ZIP9, ZIP13 and ZIP14 in human, and the same transporters in addition to ZIP1 in rodent appear to be of particular im-
portance for β-cell biology and pathology. Zinc Transporter 8 (ZnT8) which transports zinc into the insulin granules is also shown. ER = endoplas-
mic reticulum; TGN = trans-Golgi network
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rodent, and ZIP1 in rodent as potentially biologically im-
portant for β-cell function (Fig. 6). These paralogues
represent interesting targets for future investigation into
zinc regulation and homeostasis in β-cell failure and
Type 2 Diabetes.
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